New Orleans native author releases book about her health care journey with lung cancer
“Shira Kupperman Boehler called herself an avid runner. A kale enthusiast. She abides by all routine scans: annual Pap smears, colonoscopies, skin checks.”
LungDxFormer: a transformer-CNN hybrid model with dynamic spatial attention for accurate lung cancer detection and classification
“Using patient-wise cross-validation on the public LIDC-IDRI dataset, our method achieves 97.35% overall accuracy with high precision, recall, and AUC across all three classes, including the clinically challenging indeterminate class.”
What’s missing from the conversation on the ‘absurd’ new study linking vegetables to lung cancer
“New research presented at AACR on April 17 is stumping docs: 187 patients included in a USC Norris study—all diagnosed with lung cancer before age 50, with most of them being never-smokers—had higher quality diets than the average American (ie, they eat more fruits, vegetables, legumes, and whole grains).”
AACR: 2020 to 2024 Saw Drop in Number of Unique Lung Cancer Trial Sites
“(HealthDay News) — There was a decrease in the number of unique sites where phase 1 clinical trials for non-small cell lung cancer (NSCLC) were conducted between 2020 and 2024, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 17 to 22 in San Diego.”
Marshall Health Network enrolling patients in lung cancer clinical trial evaluating personalized immunotherapy approach
“The study is investigating the use of an individualized therapy designed with a tumor’s unique biology from a surgical sample to help the immune system better recognize and attack cancer cells when used alongside the immunotherapy drug pembrolizumab.”
Illusion of Comprehensive Testing in Non–Small Cell Lung Cancer: Why Coverage, Sensitivity, and Reporting Matter
“The promise of precision oncology in non-small cell lung cancer (NSCLC) rests on the ability to identify actionable genomic alterations and match patients to targeted therapies that can dramatically improve outcomes. Actionable genomic alterations are found in approximately 35%-45% of patients with NSCLC, and therefore, a significant proportion of patients stand to derive benefit. A central, yet underappreciated detail threatens to undermine this promise: not all comprehensive molecular assays are created equal. This gap between perception and reality has direct implications for patient care since incomplete molecular profiling can lead to suboptimal treatment sequencing. Incomplete molecular testing results in more than one in every eight patients with advanced NSCLC being systematically deprived of effective targeted therapy—despite having treatable, guideline-recommended biomarkers.”
Study shows new promise against locally advanced lung cancer
“New findings of an Alliance Foundation Trials study show combining immunotherapy and chemotherapy before surgery improves outcomes for some patients with locally advanced non-small cell lung cancer, according to the results of AFT-16/CHIO3 published in Lung Cancer.”
New KRAS-Targeted Drugs Show Early Signals in Advanced Lung Cancer
“In two early stage studies, the investigational drugs elisrasib and zoldonrasib were shown to shrink tumors or slow cancer growth in patients whose disease had already progressed after chemotherapy, immunotherapy and in some cases earlier targeted treatments.”
Survival outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab: a comparison between ECOG performance status 0–1 and 2
“Conclusions. ECOG PS was identified as a strong, independent prognostic factor for survival in patients with mNSCLC treated with nivolumab. In addition, negative PD-L1 expression, de novo metastatic presentation, and bone metastases were independently associated with poorer survival.”
First-Line Zongertinib Shows Strong Activity in HER2-Mutant Lung Cancer
“For years, patients with HER2-mutant non–small cell lung cancer (NSCLC) have occupied a frustrating gap in precision oncology. While targeted therapies have transformed outcomes for EGFR– and ALK-driven lung cancers, HER2-mutant disease has lagged behind, with chemotherapy remaining the standard first-line option. New data from the Phase Ia/Ib Beamion LUNG-1 trial, published in The New England Journal of Medicine, suggest that this may be changing. The oral HER2 inhibitor zongertinib demonstrated high response rates and durable clinical benefit in treatment-naïve patients, positioning it as a potential new first-line standard.”
Sustainable advocacy is the goal. Let’s unpack this together during this week’s #SundayStrides.
